Primer on Tumor Immunology and Cancer Immunotherapy™ • Nov. 7, 2019

Thursday, Nov. 7, 2019
8 a.m. 5 p.m.

Program Purpose

The understanding of cancer immunobiology has increased dramatically in recent years, leading to the successful development of novel immune-based treatment options to improve cancer patient outcomes. The SITC Primer on Tumor Immunology and Cancer Immunotherapy™ is designed to provide a foundation for understanding core immunology principles as they relate to basic and clinical research in immunotherapy of cancer.

Intended Audience

The intended audience for this annual, one-day educational program includes students, postdoctoral fellows and technicians from academia and industry, as well as physicians and scientists at more senior levels who wish to solidify their understanding of tumor immunology and immunotherapy, pharmacists, and registered nurses.

Primer Organizers

  • Michael A. Curran, PhD – The University of Texas MD Anderson Cancer Center
  • Jonathan Powell, MD, PhD – Johns Hopkins University School of Medicine
Educational Objectives

Upon completion of this meeting, participants will be able to:

  • Describe the key principles of tumor immunology and immunotherapy
  • Summarize the basic principles of passive immunotherapy, in which antibodies or T lymphocytes generated outside of the patient are administered with therapeutic intent
  • Discuss the techniques involved in active immunotherapy, including tumor antigen vaccination as well as immune checkpoint blockade
  • Outline immune monitoring techniques, both in peripheral blood and sera, as well as in patient samples collected in pre-surgical trials
  • Enhance scientific exchange with colleagues and collaborators on research and application of cancer immunotherapies to improve outcomes of patients with cancer
​​SITC's Primer on Tumor Immunology and Cancer Immunotherapy™ is supported in part by grants from Bristol-Myers Squibb, Celgene Corporation, Merck & Co., Inc. and Pfizer, Inc. (as of Sept. 13, 2019)

Program Schedule

Thursday, Nov. 7, 2019

8 a.m.

Introduction
Jonathan Powell, MD, PhD – Johns Hopkins University School of Medicine

Session 1: Tumor Immunity I

Time:

8:05 9:55 a.m.

8:05 a.m.

Adaptive Immunity to Tumors and Cytokines: Laying the Foundation for Immunotherapy
Jonathan Powell, MD, PhD – Johns Hopkins University School of Medicine

8:35 a.m.

Macrophages, Dendritic and Myeloid Cells
Tyler Curiel, MD – UT Health San Antonio

9:05 a.m.

Harnessing Natural Killer Cells and Innate Lymphoid Cells to Potentiate Antitumor Immunity
Amir Horowitz, PhD – Icahn School of Medicine at Mount Sinai

9:35 a.m.

Tumor Immunity I Panel Discussion
Moderator: Michael A. Curran, PhD – University of Texas MD Anderson Cancer Center
Panelists: 
Jonathan Powell, MD, PhD – Johns Hopkins University School of Medicine
Amir Horowitz, PhD – Icahn School of Medicine at Mount Sinai

Tyler Curiel, MD – UT Health San Antonio

9:55 a.m.

Break

Session 2: Tumor Immunity II

Time:

10:10 a.m. 12 p.m.

10:10 a.m.

Immunometabolism and the Microbiome
Greg Delgoffe, PhD – University of Pittsburgh

10:40 a.m.

Cancer Vaccines : From Ex Vivo Production to In Vivo Vaccination
Tanja de Gruijl, PhD – VU University Medical Center

11:10 a.m.

Monoclonal Antibodies and Their Derivatives
Charles G. Drake, MD, PhD – Columbia University

11:40 a.m.

Tumor Immunity II Panel Discussion
Moderator: Jonathan Powell, MD, PhD – Johns Hopkins University School of Medicine
Panelists: 
Tanja de Gruijl, PhD – VU University Medical Center
Greg Delgoffe, PhD – University of Pittsburgh
Charles G. Drake, MD, PhD – Columbia University

12 p.m.

Lunch

Session 3: Analysis of Resistance and Response

Time:

1 2:55 p.m.

1 p.m.

Introduction
Michael A. Curran, PhD – University of Texas MD Anderson Cancer Center

1:05 p.m.

Mechanisms of Extrinsic Resistance : A Miserable Microenvironment
Michael A. Curran, PhD – University of Texas MD Anderson Cancer Center

1:35 p.m.

Mechanisms of Resistance: Checkpoint Receptors
Julie R. Brahmer, MD – Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

2:05 p.m.

Biomarkers of Response to Immunotherapy
Sacha Gnjatic, PhD – Icahn School of Medicine at Mount Sinai

2:35 p.m.

Analysis of Resistance and Response Panel Discussion
Moderator: Jonathan Powell, MD, PhD – Johns Hopkins University School of Medicine
Panelists:
Julie R. Brahmer, MD – Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Michael A. Curran, PhD – University of Texas MD Anderson Cancer Center
Sacha Gnjatic, PhD – Icahn School of Medicine at Mount Sinai

2:55 p.m.

Break

Session 4: Current IO Immunotherapy

Time:

3:10 4:55 p.m.

3:10 p.m.

Adoptive T Cell Therapy
Patrick Hwu, MD – University of Texas MD Anderson Cancer Center

3:40 p.m.

Combination Therapies
Leisha Emens, MD, PhD – University of Pittsburgh

4:10 p.m.

Adverse Events
Jarushka Naidoo, M.B.B.Ch – Johns Hopkins Medicine

4:40 p.m.

Current IO Immunotherapy Panel Discussion
Moderator: Michael A. Curran, PhD – University of Texas MD Anderson Cancer Center
Panelists:
 Leisha Emens, MD, PhD – University of Pittsburgh
Patrick Hwu, MD – University of Texas MD Anderson Cancer Center
Jarushka Naidoo, M.B.B.Ch – Johns Hopkins Medicine

4:55 p.m.

Closing

5 p.m.

Adjourn

​​​​​​​​​​​​​

Schedule At-a-Glance

Wednesday, Nov. 6
World Immunotherapy Council's 3rd Young Investigator Symposium  
Novel Multi-Targeted Therapeutic Platforms
Thursday, Nov. 7

Primer on Tumor Immunology and Cancer Immunotherapy™

Social Activity:
Early Career Scientist Networking Reception

Workshop on Intratumoral Immunomodulation

Meet-the-Expert Lunch
Grant Writing Workshop
34th Annual Meeting
Friday, Nov. 8 34th Annual Meeting

Social Activity:
Poster Reception

Saturday, Nov. 9
34th Annual Meeting Social Activity:
Award Ceremony
Poster Reception
The Checkpoints Band Party
Sunday, Nov. 10 34th Annual Meeting Hot Topic Symposium